P. Alderton

ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.

M. Green, F. Muggia, M. Sobol, 1991, Cancer treatment and research.

Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.

M. Green, P. Alderton, J. Gross, 1990, Cancer research.

Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).

F. Muggia, M. Green, J. Speyer, 1990, Pharmacology & therapeutics.

Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.

M. Green, M D Green, P M Alderton, 1992, Cancer research.

Role of (±)-l,2-Bis(3,5-dioxopiperazinyl-l-yl)propane (ICRF-187) in Modulating Free Radical Scavenging Enzymes in Doxorubicin-induced Cardiomyopathy1

P. Alderton, J. Gross, M. D. Green, 2006 .